Premium
Roles of leukocytosis and cysteinyl leukotriene in polymorphonuclear leukocyte‐dependent plasma extravasation
Author(s) -
Tokita Kazutaka,
Uchida Yasuhiro,
Yamamoto Tetsuro
Publication year - 2006
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0805488
Subject(s) - extravasation , leukotriene , vascular permeability , zymosan , leukotriene b4 , platelet activating factor , degranulation , inflammation , pharmacology , immunology , chemistry , medicine , receptor , in vitro , biochemistry , asthma
The PMN‐dependent plasma extravasation is a major mechanism of permeability enhancement in acute inflammation. To reveal the pathophysiological significance of the PMN‐dependent plasma extravasation, we prepared a systemic leukocytotic guinea pig model by a daily injection of recombinant human (rh)G‐CSF. The extent of the PMN‐dependent plasma extravasation, regarded as the late‐phase permeability induced by an intradermal injection of zymosan‐activated guinea pig plasma (ZAP) or of rhC5a, clearly correlated to the circulating PMN number. The augmentation of local response following the systemic response seemed to be the characteristic feature of the PMN‐dependent plasma extravasation. We then revealed the molecular mechanism of the PMN‐dependent plasma extravasation. Neither the antihistaminic agent diphenhydramine, nor the bradykinin B2 receptor antagonist, HOE140, affected the ZAP‐induced, late‐phase extravasation. In contrast to this, pretreatment with an antagonist of cysteinyl leukotriene (cys‐LT) 1 receptor, pranlukast, significantly reduced the late‐phase extravasation. Similarly, it was reduced by pretreatment with a 5‐lipoxygenase inhibitor, MK‐886, indicating the participation of cys‐LTs in the PMN‐dependent plasma extravasation. Histologically, pretreatment with pranlukast or MK‐886 did not affect the ZAP‐induced PMN infiltration. Consistently, a combined treatment with pranlukast and diphenhydramine completely suppressed the early‐phase extravasation. As pranlukast pretreatment did not affect plasma extravasation induced by mast cell degranulation, and depletion of platelets did not influence the pranlukast‐inhibitable plasma extravasation induced by rhC5a injection, cys‐LTs are most likely produced by transcellular biosynthesis involving PMNs and vascular wall cells.